Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is indicated for the replacement of fibrinogen in patients with low plasma fibrinogen levels.

• Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) requiring fibrinogen supplementation.
• Acquired hypofibrinogenemia associated with massive hemorrhage, trauma, or surgery.
• Bleeding episodes in patients with disseminated intravascular coagulation where fibrinogen is depleted.
• Peri‑operative management of patients with anticipated fibrinogen loss during cardiac or liver transplantation.
• Supportive therapy for obstetric hemorrhage when fibrinogen levels are critically low.

Adverse reactions reported with Haemocomplettan P are generally related to the infusion process or to the protein nature of the product.

Common

• Mild fever or chills occurring during or shortly after infusion, typically self‑limiting.
• Transient headache or dizziness that resolves without intervention.
• Nausea, abdominal discomfort, or mild vomiting during the infusion period.

Serious

• Allergic reactions ranging from urticaria to anaphylaxis, requiring immediate medical attention.
• Thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, or arterial thrombosis.
• Volume overload leading to pulmonary edema, especially in patients with pre‑existing cardiac or renal disease.

When prescribing Haemocomplettan P, clinicians should consider several precautionary measures to ensure safe use.

• Verify baseline plasma fibrinogen level and monitor after administration.
• Use caution in patients with a history of thromboembolic disease.
• Assess cardiac and renal function before infusion to avoid volume overload.
• Avoid rapid infusion rates; follow recommended administration guidelines.
• Discontinue or adjust therapy if signs of allergic reaction develop.
• Consider the risk of transmission of infectious agents despite viral inactivation steps.

Haemocomplettan P may interact with other agents that affect coagulation or fluid balance, requiring attention to concurrent therapy.

Avoid

• Concomitant use of pro‑coagulant agents (e.g., activated factor VII) that could increase thrombosis risk.
• Simultaneous administration of large volumes of other plasma‑derived products without monitoring fibrinogen levels.

Use with caution

• Antifibrinolytic drugs (e.g., tranexamic acid) – monitor for excessive clot formation.
• Heparin or other anticoagulants – adjust dosing based on coagulation tests.
• Diuretics or fluid‑restrictive regimens – watch for signs of volume overload.
• Immunosuppressive therapy – observe for potential altered immune response.